サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1301433

糞便カルプロテクチン検査市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA, Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 203 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
糞便カルプロテクチン検査市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年
出版日: 2023年05月18日
発行: Transparency Market Research
ページ情報: 英文 203 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糞便カルプロテクチン検査市場- レポートの範囲

世界の糞便カルプロテクチン検査市場に関するTMRの調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も掲載しています。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、糞便カルプロテクチン検査市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の糞便カルプロテクチン検査市場の競合情勢を詳しく掘り下げています。世界の糞便カルプロテクチン検査市場で活動している主要プレーヤーが特定され、これらはさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の糞便カルプロテクチン検査市場のプレーヤーの属性です。

目次

第1章 序文

第2章 仮定と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • 技術の進歩
  • 病気疫学
  • 規制シナリオ
  • 価格分析
  • COVID-19の影響分析

第6章 世界市場の分析と予測：患者タイプ別

  • イントロダクションと定義
  • 主な調査結果／展開
  • 市場金額予測：患者タイプ別、2017-2031
    • 成人
    • 小児
  • 市場魅力分析：患者タイプ別

第7章 世界市場の分析と予測：分析タイプ別

  • イントロダクションと定義
  • 主な調査結果／展開
  • 市場金額予測：分析タイプ別、2017-2031
    • ELISA（酵素免疫吸着法）
    • 酵素フッ素免疫測定法
    • 定量免疫クロマトグラフィー
  • 市場魅力分析：分析タイプ別

第8章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果／展開
  • 市場金額予測：適応症別、2017-2031
    • 炎症性腸疾患
    • 結腸直腸がん
    • セリアック病
  • 市場魅力度分析：適応症別

第9章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果／展開
  • 市場金額予測：エンドユーザー別、2017-2031
    • 病院
    • 診断研究所
    • 学術調査機関
  • 市場魅力度分析：エンドユーザー別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場企業- 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Abbexa
    • ALPCO
    • Alpha Laboratories
    • Biomerica
    • BUHLMANN Laboratories AG
    • DRG Instruments GmbH
    • EagleBio
    • Epitope Diagnostics, Inc.
    • OPERON, SA
    • R-Biopharm AG
    • Svar Life Science
    • Thermo Fisher Scientific, Inc.
    • Werfen
    • SENTINEL CH. SpA
    • Diazyme Laboratories, Inc.
    • DiAgam
図表

List of Tables

  • Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Fecal Calprotectin Test Market Value Share, by Patient Type, 2022
  • Figure 03: Global Fecal Calprotectin Test Market Value Share, by Assay Type, 2022
  • Figure 04: Global Fecal Calprotectin Test Market Value Share, by Indication, 2022
  • Figure 05: Global Fecal Calprotectin Test Market Value Share, by End-user, 2022
  • Figure 06: Global Fecal Calprotectin Test Market Value Share, by Region, 2022
  • Figure 07: Global Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 08: Global Fecal Calprotectin Test Market (US$ Mn), by Adult, 2017-2031
  • Figure 09 Global Fecal Calprotectin Test Market (US$ Mn), by Pediatric, 2017-2031
  • Figure 10: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 11: Global Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 12: Global Fecal Calprotectin Test Market (US$ Mn), by ELISA (Enzyme linked Immunosorbent Assay), 2017-2031
  • Figure 13 Global Fecal Calprotectin Test Market (US$ Mn), by Enzyme Fluoroimmunoassay, 2017-2031
  • Figure 14: Global Fecal Calprotectin Test Market (US$ Mn), by Quantitative Immune-chromatography, 2017-2031
  • Figure 15: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 16: Global Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 17: Global Fecal Calprotectin Test Market (US$ Mn), by Inflammatory Bowel Disease, 2017-2031
  • Figure 18: Global Fecal Calprotectin Test Market (US$ Mn), by Colorectal Cancer, 2017-2031
  • Figure 19: Global Fecal Calprotectin Test Market (US$ Mn), by Celiac Disease, 2017-2031
  • Figure 20: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 21: Global Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 22: Global Fecal Calprotectin Test Market (US$ Mn), by Hospitals, 2017-2031
  • Figure 23: Global Fecal Calprotectin Test Market (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 24: Global Fecal Calprotectin Test Market (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 25: Global Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 26: Global Fecal Calprotectin Test Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 27: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 28: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: North America Fecal Calprotectin Test Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 30: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 31: North America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 32: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 33: North America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 34: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 35: North America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 36: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 37: North America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 38: North America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 39: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 40: Europe Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 41: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 42: Europe Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 43: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 44: Europe Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 45: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 46: Europe Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 47: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 48: Europe Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 49: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 50: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 52: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 53: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 54: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 55: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 56: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 57: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 58: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 60: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 61: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 62: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 63: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 64: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 65: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 66: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 67: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 68: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 69: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 70: Latin America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 72: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 73: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 74: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 75: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 76: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 77: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 78: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 79: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 80: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 81: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 82: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 83: Global Fecal Calprotectin Test Market Share, by Company, 2022
目次
Product Code: TMRGL78383

Fecal Calprotectin Test Market - Scope of Report

TMR's report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report:

  • What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
  • What are the opportunities in the global Fecal Calprotectin Test market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market - Research Objectives and Research Approach

The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fecal Calprotectin Test Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Patient Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancement
  • 5.2. Diseases Epidemiology
  • 5.3. Regulatory Scenario
  • 5.4. Pricing Analysis
  • 5.5. COVID-19 Impact Analysis

6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Patient Type, 2017-2031
    • 6.3.1. Adult
    • 6.3.2. Pediatric
  • 6.4. Market Attractiveness Analysis, by Patient Type

7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Assay Type, 2017-2031
    • 7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 7.3.2. Enzyme Fluoroimmunoassay
    • 7.3.3. Quantitative Immune-chromatography
  • 7.4. Market Attractiveness Analysis, by Assay Type

8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Inflammatory Bowel Disease
    • 8.3.2. Colorectal Cancer
    • 8.3.3. Celiac Disease
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Laboratories
    • 9.3.3. Academic & Research Institutes
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Fecal Calprotectin Test Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Patient Type, 2017-2031
    • 11.2.1. Adult
    • 11.2.2. Pediatric
  • 11.3. Market Value Forecast, by Assay Type, 2017-2031
    • 11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 11.3.2. Enzyme Fluoroimmunoassay
    • 11.3.3. Quantitative Immune-chromatography
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Inflammatory Bowel Disease
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Celiac Disease
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Academic & Research Institutes
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Patient Type
    • 11.7.2. By Assay Type
    • 11.7.3. By Indication
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Fecal Calprotectin Test Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Patient Type, 2017-2031
    • 12.2.1. Adult
    • 12.2.2. Pediatric
  • 12.3. Market Value Forecast, by Assay Type, 2017-2031
    • 12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 12.3.2. Enzyme Fluoroimmunoassay
    • 12.3.3. Quantitative Immune-chromatography
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Inflammatory Bowel Disease
    • 12.4.2. Colorectal Cancer
    • 12.4.3. Celiac Disease
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Diagnostic Laboratories
    • 12.5.3. Academic & Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Patient Type
    • 12.7.2. By Assay Type
    • 12.7.3. By Indication
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Patient Type, 2017-2031
    • 13.2.1. Adult
    • 13.2.2. Pediatric
  • 13.3. Market Value Forecast, by Assay Type, 2017-2031
    • 13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 13.3.2. Enzyme Fluoroimmunoassay
    • 13.3.3. Quantitative Immune-chromatography
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Inflammatory Bowel Disease
    • 13.4.2. Colorectal Cancer
    • 13.4.3. Celiac Disease
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Diagnostic Laboratories
    • 13.5.3. Academic & Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Patient Type
    • 13.7.2. By Assay Type
    • 13.7.3. By Indication
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Fecal Calprotectin Test Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Patient Type, 2017-2031
    • 14.2.1. Adult
    • 14.2.2. Pediatric
  • 14.3. Market Value Forecast, by Assay Type, 2017-2031
    • 14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 14.3.2. Enzyme Fluoroimmunoassay
    • 14.3.3. Quantitative Immune-chromatography
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Inflammatory Bowel Disease
    • 14.4.2. Colorectal Cancer
    • 14.4.3. Celiac Disease
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Diagnostic Laboratories
    • 14.5.3. Academic & Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Patient Type
    • 14.7.2. By Assay Type
    • 14.7.3. By Indication
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Patient Type, 2017-2031
    • 15.2.1. Adult
    • 15.2.2. Pediatric
  • 15.3. Market Value Forecast, by Assay Type, 2017-2031
    • 15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 15.3.2. Enzyme Fluoroimmunoassay
    • 15.3.3. Quantitative Immune-chromatography
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Inflammatory Bowel Disease
    • 15.4.2. Colorectal Cancer
    • 15.4.3. Celiac Disease
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Diagnostic Laboratories
    • 15.5.3. Academic & Research Institutes
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Patient Type
    • 15.7.2. By Assay Type
    • 15.7.3. By Indication
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Abbexa
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Drug Class Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Financial Overview
      • 16.3.1.5. Strategic Overview
    • 16.3.2. ALPCO
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Drug Class Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Financial Overview
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Alpha Laboratories
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Drug Class Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Financial Overview
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Biomerica
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Drug Class Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Financial Overview
      • 16.3.4.5. Strategic Overview
    • 16.3.5. BUHLMANN Laboratories AG
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Drug Class Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Financial Overview
      • 16.3.5.5. Strategic Overview
    • 16.3.6. DRG Instruments GmbH
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Drug Class Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Financial Overview
      • 16.3.6.5. Strategic Overview
    • 16.3.7. EagleBio
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Drug Class Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Financial Overview
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Epitope Diagnostics, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Drug Class Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Financial Overview
      • 16.3.8.5. Strategic Overview
    • 16.3.9. OPERON, S.A.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Drug Class Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Financial Overview
      • 16.3.9.5. Strategic Overview
    • 16.3.10. R-Biopharm AG
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Drug Class Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Financial Overview
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Svar Life Science
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Drug Class Portfolio
      • 16.3.11.3. SWOT Analysis
      • 16.3.11.4. Financial Overview
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Thermo Fisher Scientific, Inc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Drug Class Portfolio
      • 16.3.12.3. SWOT Analysis
      • 16.3.12.4. Financial Overview
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Werfen
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Drug Class Portfolio
      • 16.3.13.3. SWOT Analysis
      • 16.3.13.4. Financial Overview
      • 16.3.13.5. Strategic Overview
    • 16.3.14. SENTINEL CH. SpA
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Drug Class Portfolio
      • 16.3.14.3. SWOT Analysis
      • 16.3.14.4. Financial Overview
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Diazyme Laboratories, Inc.
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Drug Class Portfolio
      • 16.3.15.3. SWOT Analysis
      • 16.3.15.4. Financial Overview
      • 16.3.15.5. Strategic Overview
    • 16.3.16. DiAgam
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Drug Class Portfolio
      • 16.3.16.3. SWOT Analysis
      • 16.3.16.4. Financial Overview
      • 16.3.16.5. Strategic Overview